9 patents currently held

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2034. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Oct 2034

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031203220332034 20352036203720382039204020412042204320442045

notable patents all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Difluoromethyl-Aminopyridines and Difluoromethyl-Aminopyrimidines US 10,640,516

The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2035.

Ends Nov 2035 · High confidence Also notable

Treatment of Skin Lesions US 10,993,947

Granted 2021. Computed term ends 2037.

Ends Jun 2037 · High confidence Also notable

Treatment of Skin Disorders US 11,414,426

The newest of the three, granted 2022. It anchors the portfolio to 2039, later than anything else here.

Ends Apr 2039 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Sep 5, 2027
The maintenance fee for Treatment of Skin Lesions (US 11,918,586) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
1 fee due Nov 5, 2027
The maintenance fee for Difluoromethyl-Aminopyridines and Difluoromethyl-Aminopyrimidines (US 10,640,516) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Treatment of Skin Disorders	2 in force	to Jul 2039
Treatment of Skin Lesions	2 in force	to Oct 2037
Difluoromethyl-Aminopyridines and Difluoromethyl-Aminopyrimidines	2 in force	to Nov 2035
Novel Manufacturing Process for Triazine, Pyrimidine and Pyridine Derivatives	2 in force	to Apr 2035
Conformationally Restricted P13K and Mtor Inhibitors	1 in force	to Oct 2034

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 9,556,203	Conformationally Restricted P13K and Mtor Inhibitors In force Term ends Oct 3, 2034 · High confidence	In force	Term ends Oct 3, 2034	High confidence
US 10,100,031	Novel Manufacturing Process for Triazine, Pyrimidine and Pyridine Derivatives In force Term ends Apr 20, 2035 · High confidence	In force	Term ends Apr 20, 2035	High confidence
US 10,766,874	Novel Manufacturing Process for Triazine, Pyrimidine and Pyridine Derivatives In force Term ends Apr 20, 2035 · High confidence	In force	Term ends Apr 20, 2035	High confidence
US 10,640,516	Difluoromethyl-Aminopyridines and Difluoromethyl-Aminopyrimidines In force (reinstated) Term ends Nov 10, 2035 · High confidence	In force (reinstated)	Term ends Nov 10, 2035	High confidence
US 11,186,591	Difluoromethyl-Aminopyridines and Difluoromethyl-Aminopyrimidines In force Term ends Nov 10, 2035 · High confidence	In force	Term ends Nov 10, 2035	High confidence
US 10,993,947	Treatment of Skin Lesions In force Term ends Jun 12, 2037 · High confidence	In force	Term ends Jun 12, 2037	High confidence
US 11,918,586	Treatment of Skin Lesions In force Term ends Oct 14, 2037 · High confidence	In force	Term ends Oct 14, 2037	High confidence
US 11,414,426	Treatment of Skin Disorders In force Term ends Apr 29, 2039 · High confidence	In force	Term ends Apr 29, 2039	High confidence
US 12,497,407	Treatment of Skin Disorders In force Term ends Jul 9, 2039 · High confidence	In force	Term ends Jul 9, 2039	High confidence

Also on record, not counted in the 9: 1 patent in force now held by others · 3 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Torqur AG